This reduction can be partly attributed to the ability of SGLT2 inhibitors to alleviate atherosclerotic ischaemic events, which helps to minimize complications such as myocardial infarction in patients with heart failure, ultimately leading to a reduced risk of hospitalization. The gene discussed is SLC5A2; the disease is heart failure.